Holen Sie sich die Stockscreener-App
59.82
2.47%
1.44
Handel nachbörslich:
59.82
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Aberdeen Group plc Increases Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
PCVX SEC FilingsVaxcyte, Inc. 10-K, 10-Q, 8-K Forms - stocktitan.net
PCVX Should I Buy - Intellectia AI
PCVX.O Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Sell Alert: Jim Wassil Sells 2,250 Shares of Vaxcyte Inc (PCVX) - GuruFocus
Vaxcyte (PCVX) COO sells 2,250 shares in planned Rule 10b5-1 trades - stocktitan.net
James Wassil sells 7,395 PCVX shares (NASDAQ: PCVX) - stocktitan.net
Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Rating of "Moderate Buy" by Brokerages - marketbeat.com
Aug Ideas: Is now the right time to enter Vaxcyte Inc2026 Short Interest & Trade Opportunity Analysis Reports - baoquankhu1.vn
(PCVX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Vaxcyte joins elite club of stocks with RS ratings over 90 - msn.com
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - MarketScreener
Certain Pre-funded warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - marketscreener.com
Certain Restricted Stock Units of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - marketscreener.com
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - MarketScreener
Should Vaxcyte’s (PCVX) Fully Enrolled VAX-31 Phase 3 Trials Prompt a Portfolio Reassessment? - simplywall.st
Vanguard disaggregates holdings; PCVX ownership shown as 0 (PCVX) - stocktitan.net
Portfolio Update: Can Vaxcyte Inc continue delivering strong returns2026 Market WrapUp & Long Hold Capital Preservation Tips - baoquankhu1.vn
Assenagon Asset Management S.A. Increases Position in Vaxcyte, Inc. $PCVX - MarketBeat
Calif. Biotech Firm Vera Taps Vaxcyte Ex-GC As New CLO - Law360
Vaxcyte completes enrollment in two Phase 3 trials for VAX-31 - Investing.com Canada
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults - Investing News Network
Vaxcyte (PCVX) Completes Enrollment for Key Phase 3 Trials - GuruFocus
Will VAX-31’s Phase 3 OPUS Progress and Broader Serotype Coverage Change Vaxcyte’s (PCVX) Narrative - simplywall.st
Assessing Vaxcyte (PCVX) Valuation After Strong VAX 31 Phase 1/2 Results In The Lancet - simplywall.st
Responsive Playbooks and the PCVX Inflection - Stock Traders Daily
Vaxcyte Announces Significant Development of First-of-Its-Kind PCV31 - Drug Topics
PCVX PE Ratio & Valuation, Is PCVX Overvalued - Intellectia AI
JPMorgan Chase & Co. Acquires 366,266 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc.: Fundamental Analysis and Financial Ratings | 1PCVX | US92243G1085 - marketscreener.com
Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet - Investing.com Australia
Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCVX) - GuruFocus
Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCV - GuruFocus
Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet By Investing.com - Investing.com South Africa
Vaxcyte (PCVX) Advances VAX-31 Vaccine with Positive Study Resul - GuruFocus
Vaxcyte (NASDAQ:PCVX) CAO Sells $105,138.44 in Stock - MarketBeat
Vaxcyte (PCVX) Price Target Decreased by 17.52% to 83.49 - MSN
Vaxcyte : March Investor Presentation (6862ba) - MarketScreener
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate - The Manila Times
Vaxcyte Advances VAX-31 into Phase 3 Clinical Program Following Positive Phase 1/2 Study Results in Older Adults - quiverquant.com
Vaxcyte publishes positive Vax-31 phase 1/2 adult study results in The Lancet Infectious Diseases - marketscreener.com
A 31-strain pneumonia shot showed strong immune responses in adults 50+ - Stock Titan
Vaxcyte SVP, finance & CAO Cowan sells $105k in stock - Investing.com UK
Vaxcyte Publishes Positive Vax-31 Phase 1/2 Adult Study Results In The Lancet Infectious Diseases - TradingView
Positive VAX-31 Phase 1/2 Adult Data Published in The - GlobeNewswire
Vaxcyte (PCVX) finance SVP sells 1,892 shares under 10b5-1 plan - Stock Titan
Vaxcyte Completes $632.5 Million Public Offering of Common Stock - Global Legal Chronicle
Elvia Cowan sells shares; RSU vesting at PCVX (NASDAQ: PCVX) - Stock Titan
Forecast Cut: Is Vaxcyte Inc affected by consumer sentimentPortfolio Return Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):